Publicado

2022-10-29

Capacidade de formação de biofilmes e perfil de resistência de Acinetobacter baumannii isolados em unidades de terapia intensiva: uma revisão sistemática

Biofilm formation capacity and resistance profile of Acinetobacter baumannii isolated in intensive care units: A systematic review

Capacidad de formación de biopelículas y perfil de resistencia de aislados de Acinetobacter baumannii en unidades de cuidados intensivos: una revisión sistemática

DOI:

https://doi.org/10.15446/rcciquifa.v51n2.98384

Palabras clave:

Acinetobacter baumannii, unidade de terapia intensiva, biofilme, carbapenêmico, polimixina, tigeciclina (pt)
Acinetobacter baumannii, intensive care unit, biofilm, carbapenemic, polymyxin, tigecycline (en)
Acinetobacter baumannii, unidad de terapia intensiva, biopelícula, carbapenémico, polimixina, igeciclina (es)

Autores/as

  • Tábata Tauani Araújo Chagas Universidade Federal de São João del-Rei. Laboratório de Diagnóstico Laboratorial e Microbiologia Clínica. Campus Centro-Oeste Dona Lindu, Divinópolis, Minas Gerais.
  • William Gustavo Lima Universidade Federal de Minas Gerais, Faculdade de Farmácia, Belo Horizonte, Minas Gerais.
  • Magna Cristina de Paiva Universidade Federal de São João del-Rei. Laboratório de Diagnóstico Laboratorial e Microbiologia Clínica. Campus Centro-Oeste Dona Lindu, Divinópolis, Minas Gerais.
  • Adriell Pieve de Castro Universidade Federal de São João del-Rei. Laboratório de Diagnóstico Laboratorial e Microbiologia Clínica. Campus Centro-Oeste Dona Lindu, Divinópolis, Minas Gerais. https://orcid.org/0000-0002-1260-5619

Introdução: Acinetobacter baumanni é um cocobacilo Gram negativo responsável por elevadas taxas de infecções relacionadas à assistência à saúde (IRAS). Apresenta alto nível de resistência intrínseca a antimicrobianos, além da capacidade de adquirir resistência a carbapenêmicos e polimixinas. Ainda, A. baumannii possui habilidade para produzir biofilmes em superfícies abióticas e bióticas, o que favorece a infe-cção de pacientes gravemente enfermos internados em unidades de terapia inten-siva (UTI). Deve ser ressaltado que bactérias envolvidas em biofilmes apresentam maior resistência aos antimicrobianos, atribuída a fatores bioqúmicos, moleculares e as condições dos hospedeiros, o que dificulta o tratamento dessas infecções. Obje-tivos: avaliar a produção de biofilme por isolados de A. baumannii recuperados de pacientes internados em UTIs, bem como operfil de susceptibilidade a antimicro-bianos (aminoglicosídeos, tigeciclina, carbapenêmicos e polimixinas) entre esses isolados. Métodos: foi realizada uma revisão sistemática de acordo com os crité-rios Prisma nos bancos de dados Pubmed/Medline, Scopus, Lilacs, Scielo, e We b of Science. Resultados: foram incluídos um total de 12 artigos que avaliaram 1006 isolados clínicos de A. baumannii, os quais todos foram resistentes aos carbapenê-micos. No entanto, a maioria dos isolados permaneceu sensível as polimixinas B e E(94,46%). A porcentagem dos isolados produtores de biofilme foi alta (96,3%), e neste estudo não fica clara a relação entre a habilidade de produzir biofilmes e a resistência aos antimicrobianos analisados. Conclusão: mais estudos devem ser conduzidos para monitorar a resistência aos antimicrobianos em A. baumannii, sobretudo em produtores de biofilme, visto que o manejo terapêutico das infecções ocasionadas por essas linhagens torna-se mais complexo e desafiador.

Introduction:Acinetobacter baumanni is a Gram-negative coccobacillus responsible for high rates of healthcare-related infections (HAI). It has a high level of intrinsic resistance to antimicrobials, in addition to the ability to acquire resistance to carbapenems and polymyxins. Furthermore, A. baumannii has the ability to produce biofilms on abiotic and biotic surfaces, which favors the infection of critically ill patients admitted to intensive care units (ICU). It should be noted that bacteria involved in biofilms have greater resistance to antimicrobials, attributed to biochem-ical and molecular factors and the conditions of the hosts, which makes the treat-ment of these infections difficult. Objectives: To evaluate the biofilm production by A. baumannii isolates recovered from ICU patients, as well as the antimicrobial susceptibility profile (aminoglycosides, tigecycline, carbapenems and polymyxins) among these isolates. Methods: A systematic review was performed according to PRISMA criteria in the PUBMED/MEDLINE, Scopus, LILACS, SciELO, and Web of Science databases. Results: A total of 12 articles that evaluated 1006 clinical isolates of A. baumannii, all of which were resistant to carbapenems, were included. However, most isolates remained sensitive to polymyxins B and E (94.46%). The percentage of biofilm-producing isolates was high (96.3%), and in this study the relationship between the ability to produce biofilms and resistance to the analyzed antimicrobials is not clear. Conclusion: More studies should be conducted to monitor antimicrobial resistance in A. baumannii, especially in biofilm producers, as the therapeutic management of infections caused by these strains becomes more complex and challenging.

Introducción:Acinetobacter baumanni es un cocobacilo gramnegativo responsable de altas tasas de infecciones relacionadas con la salud. Tiene un alto nivel de resis-tencia intrínseca a los antimicrobianos, además de la capacidad de adquirir resis-tencia a los carbapenémicos y polimixinas. Además, A. baumannii tiene la capacidad de producir biopelículas en superficies abióticas y bióticas, lo que favorece la infec-ción de pacientes críticos ingresados en unidades de cuidados intensivos (UCI). Cabe señalar que las bacterias involucradas en biofilms tienen mayor resistencia a los antimicrobianos, atribuida a factores bioquímicos y moleculares y a las condiciones de los hospedadores, lo que dificulta el tratamiento de estas infecciones. Objetivos:evaluar la producción de biofilm por aislamientos de A. baumannii recuperados de pacientes de UCI, así como el perfil de susceptibilidad antimicrobiana (amino-glucósidos, tigeciclina, carbapenémicos y polimixinas) entre estos aislamientos. Métodos: se realizó una revisión sistemática según los criterios Prisma en las bases de datos Pubmed / Medline, Scopus, Lilacs, SciELO y Web of Science. Resultados:se incluyeron un total de 12 artículos que evaluaron 1006 aislamientos clínicos de A. baumannii, todos ellos resistentes a carbapenémicos. Sin embargo, la mayoría de los aislados permanecieron sensibles a las polimixinas B y E (94,46%). El porcen-taje de aislamientos productores de biopelículas fue alto (96,3%), y en este estudio no está clara la relación entre la capacidad de producir biopelículas y la resistencia a los antimicrobianos analizados. Conclusión: se deben realizar más estudios para monitorear la resistencia a los antimicrobianos en A. baumannii, especialmente en productores de biopelículas, ya que el manejo terapéutico de las infecciones causadas por estas cepas se vuelve más complejo y desafiante.

Referencias

P. E. Fournier, H. Richet, R. A. Weinstein. The Epidemiology and Control of Acinetobacter baumannii in Health Care Facilities. Clinical Infectious Diseases, Marseille, 42, 5, 692-699 (2006). DOI: https://doi.org/10.1086/500202

E.V. LEMOS ; F.P. de LAHOZ; T.R. EINARSON; W.F. MCGHAN; E. QUEVEDO; C. CASTAÑEDA; K. KAWAI. Carbapenem resistance and mortality in patients with Acinetobacter baumannii infection: systematic review and meta-analysis. Clinical Microbiology And Infection, Philadelphia, 20, 5, 416-423 (2014). DOI: https://doi.org/10.1111/1469-0691.12363

M. TOUCHON; J. CURY; E. YOON; L. KRIZOVA; G.C. CERQUEIRA; C. MURPHY; et al. The Genomic Diversification of the Whole Acinetobacter Genus: origins, mechanisms, and consequences. Genome Biology And Evolution, [S.L.], 6, 10,2866-2882 (2014). DOI: https://doi.org/10.1093/gbe/evu225

A. NEMEC; L. KRIZOVA; M. MAIXNEROVA; O. SEDO; S. BRISSE; P.G. HIGGINS. Acinetobacter seifertii sp. nov., a member of the Acinetobacter calcoaceticus–Acinetobacter baumannii complex isolated from human clinical specimens. International Journal Of Systematic And Evolutionary Microbiology, [S.L.],65, 3, 934-942 (2015). DOI: https://doi.org/10.1099/ijs.0.000043

C. COSGAYA; M. MARÍ-ALMIRALL; A. VAN ASSCHE; D. FERNÁNDEZ-ORTH; N. MOSQUEDA; M. TELLI; et al. Acinetobacter dijkshoorniae sp. nov., a member of the Acinetobacter calcoaceticus–Acinetobacter baumannii complex mainly recovered from clinical samples in different countries. International Journal Of Systematic And Evolutionary Microbiology, [S.L.], 66, 10, 4105-4111 (2016). DOI: https://doi.org/10.1099/ijsem.0.001318

R. LECLERCQ; R. CANTÓN; D.F.J. BROWN; C.G. GISKE; P. HEISIG; A.P. MACGOWAN; et al. EUCAST expert rules in antimicrobial susceptibility testing. Clinical Microbiology And Infection, Caen, 19, 2, 141-160 (2013). DOI: https://doi.org/10.1111/j.1469-0691.2011.03703.x

A. GIAMMANCO; C. CALÀ; T. FASCIANA; M.J. DOWZICKY. Global Assessment of the Activity of Tigecycline against Multidrug-Resistant Gram-Negative Pathogens between 2004 and 2014 as Part of the Tigecycline Evaluation and Surveillance Trial. Msphere, Palermo, 2, 1, 1-17 (2017). DOI: https://doi.org/10.1128/mSphere.00310-16

A.P. MAGIORAKOS; A. SRINIVASAN; R.B. CAREY; Y. CARMELI; M.E. FALAGAS; C.G. GISKE; et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clinical Microbiology And Infection, Stockholm, 18, 3, 268-281(2012). DOI: https://doi.org/10.1111/j.1469-0691.2011.03570.x

E. TACCONELLI; E. CARRARA; A. SAVOLDI; S. HARBARTH; M. MENDELSON; D.L. MONNET; et al. Discovery, research, and development of new antibiotics: the who priority list of antibiotic-resistant bacteria and tuberculosis. The Lancet Infectious Diseases, [S.L.],18, 3, 318-327(2018).

S. PEREZ; G.K. INNES; M.S. WALTERS; J. MEHR; J. ARIAS; R. GREELEY; et al. Increase in Hospital-Acquired Carbapenem-Resistant Acinetobacter baumannii Infection and Colonization in an Acute Care Hospital During a Surge in COVID-19 Admissions — New Jersey, February–July 2020. Mmwr. Morbidity And Mortality Weekly Report, Nova Jersey, 69,48,1827-1831 (2020). DOI: https://doi.org/10.15585/mmwr.mm6948e1

D.R. SHINOHARA; S.M.S. SAALFELD; H.V. MARTINEZ; D.D. ALTAFINI; B.B. COSTA; N.H. FEDRIGO; et al. Outbreak of endemic carbapenem-resistant Acinetobacter baumannii in a coronavirus disease 2019 (COVID-19)–specific intensive care unit. Infection Control & Hospital Epidemiology, Maringá, 1-3 (2021). DOI: https://doi.org/10.1017/ice.2021.98

D.M. SIEVERT; P. RICKS; J.R. EDWARDS; et al. Antimicrobial-Resistant Pathogens Associated with Healthcare-Associated Infections Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009–2010. Infection Control & Hospital Epidemiology, Atlanta, 34, 1, 1-14 (2013). DOI: https://doi.org/10.1086/668770

L. M. WEINER; A. K. WEBB; B. LIMBAGO; et al. Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: summary of data reported to the national healthcare safety network at the centers for disease control and prevention, 2011⠳2014. Infection Control & Hospital Epidemiology, Atlanta, 37,11,1288-1301(2016). DOI: https://doi.org/10.1017/ice.2016.174

R.H. MOGHADAM; A. ALVANDI; N. AKBARI; P. JAFARI; R. ABIRI. Assessment of biofilm formation among clinical isolates of Acinetobacter baumannii in burn wounds in the west of Iran. Cellular And Molecular Biology, Kermanshah, 64, 15, 30 (2018). DOI: https://doi.org/10.14715/cmb/2017.64.15.5

W. G. LIMA, G. C. SILVA ALVES, C. SANCHES, S. O. ANTUNES FERNANDES, & M. C. DE PAIVA. Carbapenem-resistant Acinetobacter baumannii in patients with burn injury: A systematic review and meta-analysis. Burns.(2019). DOI: https://doi.org/10.1016/j.burns.2019.07.006

M. SHARMA; N. TANEJA. Burns, antimicrobial resistance & infection control. Indian Journal Of Medical Research, Chandigarh, 6, 126, 505-507 (2007).

D.M. GUERRERO; F. PEREZ; N.G. CONGER; J.S. SOLOMKIN; M.D. ADAMS; et al. Acinetobacter baumannii-Associated Skin and Soft Tissue Infections: recognizing a broadening spectrum of disease. Surgical Infections, Cleveland, 11, 1, 49-57 (2010). DOI: https://doi.org/10.1089/sur.2009.022

C.K. MURRAY; D.R. HOSPENTHAL. Acinetobacter Infection in the ICU. Critical Care Clinics, [S.L.], 24, 2, 237-248 (2008). DOI: https://doi.org/10.1016/j.ccc.2007.12.005

P. SCOTT; G. DEYE; A. SRINIVASAN; C. MURRAY; et al. An Outbreak of Multidrug-Resistant Acinetobacter baumannii-calcoaceticus Complex Infection in the US Military Health Care System Associated with Military Operations in Iraq. Clinical Infectious Diseases, Silver Spring, 44, 12, 1577-1584 (2007). DOI: https://doi.org/10.1086/518170

C. YANG; P. SU; S. MOI; L. SHUANG. Biofilm Formation in Acinetobacter baumannii: genotype-phenotype correlation. Molecules, Kaohsiung, 24, 10, 1849 (2019). DOI: https://doi.org/10.3390/molecules24101849

M. RIPA; L. GALLU; A. POLI; C. OLTOLINI; et al. Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors. Clinical Microbiology And Infection, Milão, 27, 3, 451-457 (2021). DOI: https://doi.org/10.1016/j.cmi.2020.10.021

J. RODRÍGUEZ-BAÑO; S. MARTÍ; S. SOTO; F. FERNÁNDEZ-CUENCA; et al. Biofilm formation in Acinetobacter baumannii: associated features and clinical implications. Clinical Microbiology And Infection, Sevilla,14, 3, 276-278 (2008). DOI: https://doi.org/10.1111/j.1469-0691.2007.01916.x

M.V. VILLEGAS; A.I. HARTSTEIN. Acinetobacter Outbreaks, 1977–2000. Infection Control & Hospital Epidemiology, Cali, 24, 4, 284-295 (2003). DOI: https://doi.org/10.1086/502205

R. DJERIBI; W. BOUCHLOUKH; T. JOUENNE; B. MENAA. Characterization of bacterial biofilms formed on urinary catheters. American Journal Of Infection Control, Annaba, 40, 9, 854-859 (2012). DOI: https://doi.org/10.1016/j.ajic.2011.10.009

S. GIL-PEROTIN; P. RAMIREZ; V. MARTI; J.M. SAHUQUILLO; E. GONZALEZ; et al.Implications of endotracheal tube biofilm in ventilator-associated pneumonia response: a state of concept. Critical Care, Valencia, 16, 3, 1-23 (2012). DOI: https://doi.org/10.1186/cc11357

J.P.T. HIGGINS, S. GREENS (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.

C. GREENE; J. WU; A.H. RICKARD; C. XI. Evaluation of the ability of Acinetobacter baumannii to form biofilms on six different biomedical relevant surfaces. Letters In Applied Microbiology, Ann Arbor, 63, 4, 233-239 (2016). DOI: https://doi.org/10.1111/lam.12627

R. DONLAN. Biofilms and Device-Associated Infections. Emerging Infectious Diseases, Atlanta, 7, 2, 277-281 (2001). DOI: https://doi.org/10.3201/eid0702.010226

B.W. TRAUTNER; DAROUICHE, R. O. Role of biofilm in catheter-associated urinary tract infection. American Journal Of Infection Control, Holcombe Blvd, 32, 3, 177-183 (2004). DOI: https://doi.org/10.1016/j.ajic.2003.08.005

C. AMBROSI; D. SCRIBANO; M. ALEANDRI; C. ZAGAGLIA; L. FRANCESCO; et al. Acinetobacter baumannii Virulence Traits: a comparative study of a novel sequence type with other italian endemic international clones. Frontiers In Microbiology, Roma, 8, 1977, 1-11 (2017). DOI: https://doi.org/10.3389/fmicb.2017.01977

G.M. CERQUEIRA; A.Y. PELEG. Insights into Acinetobacter baumannii pathogenicity. Iubmb Life, Dubai, 63, 12, 1055-1060 (2011). DOI: https://doi.org/10.1002/iub.533

E. BABAPOUR; A. HADDADI; R. MIRNEJAD; S. ANGAJI; N. AMIRMOZAFARI. Biofilm formation in clinical isolates of nosocomial Acinetobacter baumannii and its relationship with multidrug resistance. Asian Pacific Journal Of Tropical Biomedicine, Tehran, 6, 6, 528-533 (2016). DOI: https://doi.org/10.1016/j.apjtb.2016.04.006

R. RANJBAR; A. FARAHANI. Study of genetic diversity, biofilm formation, and detection of Carbapenemase, MBL, ESBL, and tetracycline resistance genes in multidrug-resistant Acinetobacter baumannii isolated from burn wound infections in Iran. Antimicrobial Resistance & Infection Control, Tehran, 8, 172, 1-26 (2019). DOI: https://doi.org/10.1186/s13756-019-0612-5

S.B. FREITAS; S.C. AMARAL; M.R.A. FERREIRA; B.C. ROLOFF; et al. Molecular Characterization of Carbapenem-Resistant Acinetobacter baumannii Associated with Nosocomial Infection in the Pelotas, RS, Brazil. Current Microbiology, Pelotas, 77, 10, 2724-2734 (2020). DOI: https://doi.org/10.1007/s00284-020-02060-w

K. PARK; J. SHIN; S.Y. LEE; S.H. KIM; M.O. JANG; et al. The Clinical Characteristics, Carbapenem Resistance, and Outcome of Acinetobacter Bacteremia According to Genospecies. Plos One, Gwang-Ju, 8, 6, 15 (2013). DOI: https://doi.org/10.1371/journal.pone.0065026

W.G. LIMA; J.C.M. BRITO; W.S.C. NIZER. Ventilator-associated pneumonia (VAP) caused by carbapenem-resistant Acinetobacter baumannii in patients with COVID-19: two problems, one solution?. Medical Hypotheses, Belo Horizonte, 144, 110139 (2020). DOI: https://doi.org/10.1016/j.mehy.2020.110139

E. SHARIFIPOURS; S. SHAMS; M. ESMKHANI; J. KHODADADI; et al. Evaluation of bacterial co-infections of the respiratory tract in COVID-19 patients admitted to ICU. Bmc Infectious Diseases, Qom, 20, 1, 646 (2020). DOI: https://doi.org/10.1186/s12879-020-05374-z

Q.YIN; L. WU; F. NIU; et al.The correlation between the biofilm formation ability and the drug resistance of Acinetobacter baumannii. International Journal Of Clinical And Experimental Medicine, Zhenjiang, 13, 4, 2731-2737 (2020).

L. POIREL, T. NAA; P. NORDMANN. Diversity, epidemiology, and genetics of class D β-lactamases. Antimicrobial Agents and Chemotherapy, Le Kremlin-Bicetre 54, 1, 24-38 (2010). DOI: https://doi.org/10.1128/AAC.01512-08

P. NOWAK; P. PALUCHOWSKA. Acinetobacter baumannii: biology and drug resistance - role of carbapenemases. Folia Histochem Cytobiol.54(2):61-74 (2016). DOI: https://doi.org/10.5603/FHC.a2016.0009

H. ZEIGHAMI; F. VALADKHANI; R. SHAPOURI; E. SAMADI; F. HAGHI. Virulence characteristics of multidrug resistant biofilm forming Acinetobacter baumannii isolated from intensive care unit patients. Bmc Infectious Diseases, [S.L.], 19, 629, 1-9 (2019). DOI: https://doi.org/10.1186/s12879-019-4272-0

A.L.P. DA COSTA; A.C.S.S. JUNIOR. Resistência bacteriana aos antibióticos e Saúde Pública: uma breve revisão de literatura. Macapá., 7, 2, 45-57 (2017). DOI: https://doi.org/10.18468/estcien.2017v7n2.p45-57

C.A.C. MENDES; E.A. BURDMANN. Polimixinas: revisão com ênfase na sua nefrotoxicidade. Revista da Associação Médica Brasileira, São Paulo, 55, 6, 752-759 (2009). DOI: https://doi.org/10.1590/S0104-42302009000600023

M.D. ALCÁNTAR-CURIEL; R. ROSALES-REYES; M. D. JARILLO-QUIJADA; C. GAYOSSO-VÁZQUEZ; J.L. FERNÁNDEZ-VÁZQUEZ; J.E. TOLEDANO-TABLEROS; et al.; Carbapenem-Resistant Acinetobacter baumannii in Three Tertiary CareHospitals in Mexico: virulence profiles, innate immune response and clonal dissemination. Frontiers In Microbiology, Cidade do México,10,2116,1-19 (2019). DOI: https://doi.org/10.3389/fmicb.2019.02116

W. G. LIMA, M. C. ALVES, W. S. CRUZ, M. C. PAIVA. Chromosomally encoded and plasmid-mediated polymyxins resistance in Acinetobacter baumannii: a huge public health threat. European Journal of Clinical Microbiology & Infectious Diseases, 37(6), 1009–1019 (2018). DOI: https://doi.org/10.1007/s10096-018-3223-9

W. G. LIMA, J. C. M. BRITO, B. G. CARDOSO, V. N. CARDOSO, M. C. DE PAIVA, M. E.DE LIMA, S. O. FERNANDES. Rate of polymyxin resistance among Acinetobacter baumannii recovered from hospitalized patients: a systematic review and meta-analysis. European Journal of Clinical Microbiology & Infectious Diseases, 39(8), 1427–1438 (2020). DOI: https://doi.org/10.1007/s10096-020-03876-x

L.A. ARROYO; I. MATEOS; GONZÁLEZ; J. AZNAR. In Vitro Activities of Tigecycline, Minocycline, and Colistin-Tigecycline Combination against Multi- and Pandrug-Resistant Clinical Isolates of Acinetobacter baumannii Group. Antimicrobial Agents And Chemotherapy, Seville, 53, 3, 1295-1296 (2009). DOI: https://doi.org/10.1128/AAC.01097-08

G.L. GENTELUCI; D.B.C. GOMES; M.J. SOUZA; K.R. CARVALHO ; M.H.S. VILLAS-BÔAS. Emergence of polymyxin B-resistant Acinetobacter baumannii in hospitals in Rio de Janeiro. Jornal Brasileiro de Patologia e Medicina Laboratorial, Rio de Janeiro, 52, 2, 91-95 (2016). DOI: https://doi.org/10.5935/1676-2444.20160021

K. S. KO; J. Y. SUH; K. T. KWON; S.-I. JUNG; et al. High rates of resistance to colistin and polymyxin B in subgroups of Acinetobacter baumannii isolates from Korea. Journal Of Antimicrobial Chemotherapy, Suwon, 60, 5, 1163-1167 (2007). DOI: https://doi.org/10.1093/jac/dkm305

T.V. DALMOLIN. Resistência ás polimixinas: caracterização molecular (foco no gene mcr-1) e avaliação de métodos de detecção.118 f. Dissertação (Mestrado) - Curso de Farmácia, Universidade Federal do Rio Grande do Sul. Faculdade de Farmácia. Programa de Pós-Graduação em Ciências Farmacêuticas., Porto Alegre (2018).

F. HAMEED; M.A. KHAN; H. MUHAMMAD; T. SARWAR; H. BILAL; T.U REHMAN. Plasmid-mediated mcr-1 gene in Acinetobacter baumannii and Pseudomonas aeruginosa: first report from Pakistan. Revista da Sociedade Brasileira de Medicina Tropical, KhyberPakhtunkhwa, 52, 1-6 (2019). DOI: https://doi.org/10.1590/0037-8682-0237-2019

N. MARTINS-SORENSON; E. SNESRUD; D.E. XAVIER; L.C. ; CACCI; A.T IAVARONE,; et al. A novel plasmid-encoded mcr-4.3 gene in a colistin-resistant Acinetobacter baumannii clinical strain. Journal Of Antimicrobial Chemotherapy, 75,1,60-64 (2019). DOI: https://doi.org/10.1093/jac/dkz413

C.A MOUBARECK.; D.H. HALAT. Insights into Acinetobacter baumannii: a review of microbiological, virulence, and resistance traits in a threatening nosocomial pathogen. Antibiotics, Beirut, 9, 3, 119 (2020). DOI: https://doi.org/10.3390/antibiotics9030119

A. SZCZYPTA; K. TALAGA-ĆWIERTNIA; M. KIELAR; P. KRZYśCIAK; A. GAJEWSKA; et al. Investigation of Acinetobacter baumannii Activity in Vascular Surgery Units through Epidemiological Management Based on the Analysis of Antimicrobial Resistance, Biofilm Formation and Genotyping. International Journal Of Environmental Research And Public Health, Cracóvia,18, 4,1563 (2021). DOI: https://doi.org/10.3390/ijerph18041563

S.R.A. CASTILHO; C.S.M. GODOY; A.O. GUILARDE; J.L. CARDOSO; M.C.P. ANDRÉ;A.P. JUNQUEIRA-KIPNIS; et al. Acinetobacter baumannii strains isolated from patients in intensive care units in Goiânia, Brazil: molecular and drug susceptibility profiles. Plos One, Goiás, 12, 5, 1-13 (2017). DOI: https://doi.org/10.1371/journal.pone.0176790

S. KHOSHNOOD; M. SAVARI; E.A. MONTAZERI; A.F. SHEIKH. Survey on Genetic Diversity, Biofilm Formation, and Detection of Colistin Resistance Genes in Clinical Isolates of Acinetobacter baumannii. Infection And Drug Resistance, Ahvaz, 13, 1547-1558 (2020). DOI: https://doi.org/10.2147/IDR.S253440

M.J. MCCONNELL; L. ACTIS; J. PACHÓN. Acinetobacter baumannii: human infections, factors contributing to pathogenesis and animal models. Fems Microbiology Reviews, Sevilla, 37, 2, 130-155 (2013). DOI: https://doi.org/10.1111/j.1574-6976.2012.00344.x

I. ROCA; P. ESPINAL; X. VILA-FARRÉS; J. VILA.The Acinetobacter baumannii Oxymoron: commensal hospital dweller turned pan-drug-resistant menace. Frontiers In Microbiology, Barcelona, 3, 148, 1-115 (2012). DOI: https://doi.org/10.3389/fmicb.2012.00148

L.B. KING; E. SWIATLO; A. SWIATLO; L.S. MCDANIEL. Serum resistance and biofilm formation in clinical isolates of Acinetobacter baumannii. Fems Immunology & Medical Microbiology, Jackson, 55, 3,414-421 (2009). DOI: https://doi.org/10.1111/j.1574-695X.2009.00538.x

B.A. EIJKELKAMP; U.H. STROEHER; K.A. HASSAN; M.S. PAPADIMITRIOUS; I.T. PAULSEN; M.H. BROWN. Adherence and motility characteristics of clinical Acinetobacter baumannii isolates. Fems Microbiology Letters, Adelaide,323, 1, 44-51 (2011). DOI: https://doi.org/10.1111/j.1574-6968.2011.02362.x

R. M. DONLAN; J. W. COSTERTON. Biofilms: survival mechanisms of clinically relevant microorganisms. Clinical Microbiology Reviews, Atlanta,15, 2,167-193 (2002). DOI: https://doi.org/10.1128/CMR.15.2.167-193.2002

L.C. B.S. OLIVEIRA; P.P.M. CARNEIRO; R.G. FISCHER; E.M.B. TINOCO. A presença de patógenos respiratórios no biofilme bucal de pacientes com pneumonia nosocomial. Revista Brasileira de Terapia Intensiva, [S.L.], 19, 4, 428-433 (2007). DOI: https://doi.org/10.1590/S0103-507X2007000400004

A.M. SHENKUTIE; M. Z.YAO; G.K. SIU; Barry K.C. WONG; P.H. LEUNG. Biofilm-Induced Antibiotic Resistance in Clinical Acinetobacter baumannii Isolates. Antibiotics, Hong Kong, 9, 11, 817 (2020). DOI: https://doi.org/10.3390/antibiotics9110817

R.L. BOONE; B. WHITEHEAD; T.M. AVERY; J. LU; J.D. FRANCIS; M.A. GUEVARA; et al. Analysis of virulence phenotypes and antibiotic resistance in clinical strains of Acinetobacter baumannii isolated in Nashville, Tennessee. Bmc Microbiology, Nashville, 21, 1, 1-12, 9 (2021). DOI: https://doi.org/10.1186/s12866-020-02082-1

M. FRIERI; K. KUMAR; A. BOUTIN. Antibiotic resistance. Journal Of Infection And Public Health, Nova York, 10, 4, 369-378 (2017). DOI: https://doi.org/10.1016/j.jiph.2016.08.007

C.W. HALL; T. MAH. Molecular mechanisms of biofilm-based antibiotic resistance and tolerance in pathogenic bacteria. Fems Microbiology Reviews, [S.L.], 41, 3, 276-301, (2017). DOI: https://doi.org/10.1093/femsre/fux010

P. KRZYśCIAK; A. CHMIELARCZYK; M. POBIEGA; ROMANISZYN, D.; J. WÓJKOWSKA‐MACH. Acinetobacter baumannii isolated from hospital‐acquired infection: biofilm production and drug susceptibility. Apmis, Cracóvia, 125, 11,1017-1026 (2017). DOI: https://doi.org/10.1111/apm.12739

A.V.A. LIMA; S.M.SILVA; J.A.A. NASCIMENTO JÚNIOR; M.S. CORREIA; A.C. LUZ; et al.Occurrence and Diversity of Intra- and Interhospital Drug-Resistant and Biofilm-Forming Acinetobacter baumannii and Pseudomonas aeruginosa. Microbial Drug Resistance, [S.I.],26, 7, 802-814 (2020). DOI: https://doi.org/10.1089/mdr.2019.0214

Cómo citar

APA

Araújo Chagas, T. T., Lima, W. G., de Paiva, M. C. y Pieve de Castro, A. (2022). Capacidade de formação de biofilmes e perfil de resistência de Acinetobacter baumannii isolados em unidades de terapia intensiva: uma revisão sistemática. Revista Colombiana de Ciencias Químico-Farmacéuticas, 51(2). https://doi.org/10.15446/rcciquifa.v51n2.98384

ACM

[1]
Araújo Chagas, T.T., Lima, W.G., de Paiva, M.C. y Pieve de Castro, A. 2022. Capacidade de formação de biofilmes e perfil de resistência de Acinetobacter baumannii isolados em unidades de terapia intensiva: uma revisão sistemática. Revista Colombiana de Ciencias Químico-Farmacéuticas. 51, 2 (oct. 2022). DOI:https://doi.org/10.15446/rcciquifa.v51n2.98384.

ACS

(1)
Araújo Chagas, T. T.; Lima, W. G.; de Paiva, M. C.; Pieve de Castro, A. Capacidade de formação de biofilmes e perfil de resistência de Acinetobacter baumannii isolados em unidades de terapia intensiva: uma revisão sistemática. Rev. Colomb. Cienc. Quím. Farm. 2022, 51.

ABNT

ARAÚJO CHAGAS, T. T.; LIMA, W. G.; DE PAIVA, M. C.; PIEVE DE CASTRO, A. Capacidade de formação de biofilmes e perfil de resistência de Acinetobacter baumannii isolados em unidades de terapia intensiva: uma revisão sistemática. Revista Colombiana de Ciencias Químico-Farmacéuticas, [S. l.], v. 51, n. 2, 2022. DOI: 10.15446/rcciquifa.v51n2.98384. Disponível em: https://revistas.unal.edu.co/index.php/rccquifa/article/view/98384. Acesso em: 13 oct. 2024.

Chicago

Araújo Chagas, Tábata Tauani, William Gustavo Lima, Magna Cristina de Paiva, y Adriell Pieve de Castro. 2022. «Capacidade de formação de biofilmes e perfil de resistência de Acinetobacter baumannii isolados em unidades de terapia intensiva: uma revisão sistemática». Revista Colombiana De Ciencias Químico-Farmacéuticas 51 (2). https://doi.org/10.15446/rcciquifa.v51n2.98384.

Harvard

Araújo Chagas, T. T., Lima, W. G., de Paiva, M. C. y Pieve de Castro, A. (2022) «Capacidade de formação de biofilmes e perfil de resistência de Acinetobacter baumannii isolados em unidades de terapia intensiva: uma revisão sistemática», Revista Colombiana de Ciencias Químico-Farmacéuticas, 51(2). doi: 10.15446/rcciquifa.v51n2.98384.

IEEE

[1]
T. T. Araújo Chagas, W. G. Lima, M. C. de Paiva, y A. Pieve de Castro, «Capacidade de formação de biofilmes e perfil de resistência de Acinetobacter baumannii isolados em unidades de terapia intensiva: uma revisão sistemática», Rev. Colomb. Cienc. Quím. Farm., vol. 51, n.º 2, oct. 2022.

MLA

Araújo Chagas, T. T., W. G. Lima, M. C. de Paiva, y A. Pieve de Castro. «Capacidade de formação de biofilmes e perfil de resistência de Acinetobacter baumannii isolados em unidades de terapia intensiva: uma revisão sistemática». Revista Colombiana de Ciencias Químico-Farmacéuticas, vol. 51, n.º 2, octubre de 2022, doi:10.15446/rcciquifa.v51n2.98384.

Turabian

Araújo Chagas, Tábata Tauani, William Gustavo Lima, Magna Cristina de Paiva, y Adriell Pieve de Castro. «Capacidade de formação de biofilmes e perfil de resistência de Acinetobacter baumannii isolados em unidades de terapia intensiva: uma revisão sistemática». Revista Colombiana de Ciencias Químico-Farmacéuticas 51, no. 2 (octubre 23, 2022). Accedido octubre 13, 2024. https://revistas.unal.edu.co/index.php/rccquifa/article/view/98384.

Vancouver

1.
Araújo Chagas TT, Lima WG, de Paiva MC, Pieve de Castro A. Capacidade de formação de biofilmes e perfil de resistência de Acinetobacter baumannii isolados em unidades de terapia intensiva: uma revisão sistemática. Rev. Colomb. Cienc. Quím. Farm. [Internet]. 23 de octubre de 2022 [citado 13 de octubre de 2024];51(2). Disponible en: https://revistas.unal.edu.co/index.php/rccquifa/article/view/98384

Descargar cita

CrossRef Cited-by

CrossRef citations0

Dimensions

PlumX

Visitas a la página del resumen del artículo

360

Descargas

Los datos de descargas todavía no están disponibles.